gMG is different from ocular myasthenia gravis ... how they’ll determine whether Ultomiris is a suitable treatment for your form of myasthenia gravis. The exact way Ultomiris works to treat ...

Richard J. Nowak, MD, MS, Yale School of Medicine, explains what some early myasthenia gravis symptoms are and their impact on research efforts.

Highlights in myasthenia gravis from AAN 2025 include trials of new therapy inebilizumab, new data on the approved rozanolixizumab for ocular symptoms, and insights into current clinical practice.

The U.S. FDA approval of Johnson & Johnson’s Imaavy (nipocalimab-aahu) for myasthenia gravis brings the monoclonal antibody into a treatment space that teems with competition, both approved and ...

"I recommend always having neurophysiological testing and not making a diagnosis of myasthenia based only on the LRP4 antibodies. Although there is a tendency for these patients to be treatment ...

leading patient advocacy organization solely dedicated to the myasthenia gravis community kicked off its annual conference today with sessions about treatment progress as well as important patient ...

The most dramatic response is usually seen in patients with ocular difficulties ... intolerable side effects or failure of treatment, other immunosuppressants may be used, most commonly Imuran.